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EAbstract
Introduction: The aim of this study was to investigate whether there is an increased susceptibility to apoptosis in cultured
fibroblasts from patients with schizophrenia.
Method: Dermal fibroblasts were collected and cultured from three groups: patients with schizophrenia, patients with non-
schizophrenic psychosis, and healthy comparison subjects. Susceptibility to apoptosis was measured at the level of degradation
product (proportion of cells in the sub-G0 cell cycle fraction in which apoptotic bodies accumulate), pro-apoptotic effector
(activated caspase-3), and molecular regulators (P53, Bax and Bcl-2). Cell lines were studied under both basal culture and
cycloheximide (an apoptotic inducer) exposure conditions.
Results: Consistent with increased susceptibility to apoptosis, the proportion of sub-G0 cells under basal conditions was
significantly larger in the schizophrenia group, compared to the non-schizophrenic psychosis group. However when apoptosis
was stimulated with cycloheximide, the schizophrenia group showed an attenuated caspase-3 response. The pattern of
correlations between regulators, caspase-3 and the proportion of sub-G0 cells was different in the schizophrenia group,
consistent with group-specific apoptotic pathway dysregulation.U
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V.S. Catts et al. / Schizophrenia Research xx (2006) xxx–xxx2Conclusion: The study demonstrated anomalous apoptotic mechanisms in schizophrenia, which appear not to affect non-
schizophrenia psychosis patients. The detection of these anomalies in fibroblasts suggests that altered apoptosis may be
observable in all somatic cell types in schizophrenia.
D 2006 Published by Elsevier B.V.
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1. Introduction
The evidence of reduced incidence rates of cancer
in schizophrenia (for a recent review, see Grinshpoon
et al., 2005) was advanced in support of the
hypothesis that increased susceptibility to apoptosis
is implicated in the pathophysiology of schizophrenia
(Catts and Catts, 2000). The rationale for this proposal
was based upon the role of apoptosis in protecting
against malignancy. Apoptotic regulators check DNA
integrity at all stages of the cell cycle. If DNA damage
is detected, cell cycle progression is arrested to allow
repair of damaged DNA. If DNA repair is not
possible, the potentially pre-cancerous cell normally
undergoes apoptosis and is eliminated.
The current study was designed to carry out a
multi-level functional assessment of apoptosis in
living cells—at the level of regulators (P53, Bax
and Bcl-2), effectors (caspase-3), and degradation
products (apoptotic bodies). Phosphorylation of the
transcription factor P53 increases levels of the pro-
apoptotic protein Bax. Homodimerisation of Bax
results in mitochondrial release of cytochrome C,
which activates proteolytic enzymes called caspases in
the cytosol. Caspase activation leads to DNA frag-
mentation and cell death. As the dying cell shrinks,
the plasma membrane forms convolutions around
cellular contents (dblebbingT), which sequester to form
dapoptotic bodiesT containing DNA fragments. The
anti-apoptotic protein, Bcl-2 keeps this process in
check by forming Bax-Bcl-2 heterodimers, preventing
Bax–Bax Homodimerisation.
We measured apoptotic markers in cultured dermal
fibroblasts, based on the assumption that systemic
cancer resistance would be related to altered apoptotic
mechanisms in all cell types. Cultured dermal
fibroblasts have been demonstrated to be a convenient
and useful model for investigating schizophrenia
(Mahadik and Mukherjee, 1996). The primary culture
can be maintained in vitro for many cell passagesOO
F
overcoming the confounding effects of medications
taken by the patients at the time of biopsy, barring
prolonged medication-induced gene expression
changes via epigenetic modification. By assessing
cells under basal culture conditions, apoptotic mech-
anisms could be studied when not challenged by an
apoptotic stimulus. By exposing cells to cyclohexi-
mide, mechanisms could be assessed when cells were
undergoing an active apoptotic response.ED
 P2. Materials and methods
2.1. Subject recruitment and assessment
The study was approved by Griffith University and
Wolston Park Hospital Institutional Ethics Commit-
tees. Subjects provided written informed consent. Full
details of the subject recruitment procedures are
provided elsewhere (McGrath et al., 2000). Subjects
were assessed with the Diagnostic Interview for
Psychosis (Jablensky et al., 1999) and diagnosed
according to DSM-III-R. Patients in the schizophrenia
group (n =10) were diagnosed with schizophrenia (7
males, 3 females; mean age 38F10). The non-
schizophrenic psychosis (NSP) group (n =11) includ-
ed six patients with Bipolar Disorder (Episode(s) With
Psychotic Features), four with Major Depressive
Episode With Psychotic Features, and one patient
with Psychotic Disorder Not Otherwise Specified
(Atypical Psychosis) (6 males, 5 females; mean age
41F10). There were 10 healthy controls (6 males, 4
females; mean age 39F13). Groups did not differ
significantly in terms of age (F =0.261, df =2, 28,
p =0.772) or sex ( p =0.764).
2.2. Specimen collection and cell culture
Human dermal fibroblasts were cultured by explant
growth from skin obtained by biopsy from the upper
TARTICLE IN PRESS
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
V.S. Catts et al. / Schizophrenia Research xx (2006) xxx–xxx 3UN
CO
RR
EC
inside arm, under local anaesthesia using a 5 mm
disposable punch. Initial cell line culture procedures
were based on those of Edelstein and Breakefield
(1980). Fibroblasts were then cryogenically stored in
liquid nitrogen.
2.3. Experimental procedures
Full details of laboratory procedures are available
on request. The experimenter (VSC) was blind to
group membership of cell lines. Cell lines were
cultured under proliferating conditions in complete
DMEM (containing 10% fetal bovine serum and 50
ng/ml gentamycin) over a period of about two to three
weeks. An aliquot of about 6.5 million cells was
plated into each of 6 culture flasks at a density of
10,000 cells/cm2. After 48 h incubation, cyclohexi-
mide (200 Ag/Al methanol; Calbiochem) at a concen-
tration of 200 Ag/ml of culture medium was added to
three flasks. Nothing was added to the three flasks
containing the untreated cell lines. All experimental
procedures were carried out in duplicate.
2.4. Flow cytometry analysis
Flow cytometry measures the distribution of cells
in the different cell cycle phases by sorting and
counting cells according to DNA content. Cells were
fixed in 250 Al ice-cold PBS followed by a 250 Al
ice-cold 60% ethanol and stored at 4 8C. Prior to
analysis, the cells were resuspended in 500 Al warm
PBS, 1 Ag RNase and 25 Ag propidium iodide for
30 min in the dark. Flow cytometric analysis was
performed on a BD Calibur flow cytometer.
Percentage of cells was determined for each of the
following cell cycle phases: G0/G1 (46 chromo-
somes); S (greater than 46 chromosomes, less than
92 chromosomes); G2/M (92 chromosomes); and
polyploid (greater than 92 chromosomes). Cells with
a DNA content of less than 46 chromosomes were
designated as being sub-G0 (including apoptotic
bodies).
2.5. Western blot analysis of Bax, Bcl-2, phosphorylated
P53P392Ser and actin protein
Western blot analyses of whole cell lysates were
performed using standard procedures. Protein wasED
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extracted in an ice-cold lysis buffer (50 mM Tris.HCl,
pH 7.5; 150 mM NaCl; 1% Nonidet P40; 0.5%
sodium deoxycholate; 0.1% SDS; 1% protease inhib-
itor cocktail [Sigma]). To enable comparison across
gels, an aliquot of cell lysate from the breast cancer
cell line MCF-7 was included in each blot. The
primary antibodies used were rabbit anti-Bax 1:20
(Oncogene); rabbit anti-Bcl-2 1:50 (Oncogene); rabbit
anti-actin 1:200 (Sigma); mouse anti-phosphorylated
P53P392Ser 1:200 (Alexis) and horseradish peroxidase
conjugated secondary antibodies used were anti-
mouse (BioRad); anti-rabbit (BioRad), both 1:50,000.
Band volumes were determined using Quantity One
4.4.0. Band volumes for Bax, Bcl-2, phosphorylated
P53P392Ser and actin protein were divided by the
corresponding band volume of the MCF-7 cell lysate;
and, loading errors of Bax, Bcl-2 and phosphorylated
P53P392Ser were controlled for by dividing with the
adjusted actin band volume.
2.6. Caspase-3 activity assay
Levels of caspase-3 activity were derived from a
fluorometric assay involving the cleavage of the
synthetic substrate, DEVD-AFC, by caspase-3 accord-
ing to the manufacturers instructions (Clontech).
2.7. Data analysis
Data analysis of laboratory measures was per-
formed using the mean of the two independent
determinations of each measure. Significant outliers
( p b0.01) were assessed within each diagnostic
group using Grubb’s method. Three outliers were
detected and replaced with the highest value plus
one unit for that variable within that diagnostic
group, in accordance with standard procedure
(Tabanick and Fidell, 2001). Across the matrix there
were less than 3% missing data, missing at random
due to technical errors. Estimation maximisation was
used to replace these missing values using all
categorical and continuous data to perform this
procedure.
We conservatively conceptualised the experiment
as a two-way factorial design, with one between-
groups (diagnosis) and one within-groups (treatment)
independent variable. Diagnosis had three levels:
schizophrenia group, NSP group, and healthy com-
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mide exposure and no treatment (basal condition). A
multivariate analysis of variance (MANOVA) was
performed to assess overall effects of group and
treatment. While one of the assumptions of MAN-
OVA (that there be more subjects in the smallest cell
than DVs) is violated (the smallest cell contains the
same number of subjects as DVs), overall this
technique was considered a conservative preparatory
analysis for the univariate post-hoc testing. Significant
effects detected by the MANOVAwere explored usingUN
CO
RR
EC
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Fig. 1. Cell cycle distribution. The basal and cycloheximide (CHX) ind
determined for fibroblast cells from patients with schizophrenia (continuous
triangles) and non-affected controls (dashed line/squares).univariate ANOVA and Tukey’s post-hoc test. Corre-
lations between markers were assessed using Pear-
son’s coefficients.3. Results
3.1. Overall effects on laboratory measures
The MANOVA including laboratory measures
showed a significant overall effect of treatmentED
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uced average proportionsFS.E.M. of cell cycle distribution were
line/circles), patients with non-schizophrenic psychosis (dotted line/
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(F =10.704, df =1, 60, p =0.000) and diagnostic
group (F =1.715, df =2, 59, p =0.044).
3.2. Treatment effects
The results of flow cytometry analysis for each
diagnostic group are presented in Fig. 1. Points on
the left of each graph are values for cell lines under
basal conditions. Points on the right of each graph
are values for cell lines exposed to cycloheximide.
The MANOVA detected a significant effect of
cycloheximide treatment on: 1) the proportion of
cells in G0/G1 (F =14.843, df =1, 29, p =0.000), 2)
the proportion of cells in G2/M (F =49.589, df =1,
29, p =0.000), and 3) the proporti on of polyploid
cells (F =4.115, df =1, 29, p=0.047). Cycloheximide
exposure was associated with an across-group
reduction in the proportion of cells in G0/G1 from
57% to 49%; and, increases in the proportion of cells
in G2/M from 13% to 18%, and polyploid phase,
from 9% to 10%. There was no significant effect of
cycloheximide exposure on sub-G0 (F =0.543,
df =1, 29, p =0.464) or S phase (F =0.088, df =1,
29, p =0.768).
Treatment effects on caspase activity levels for
each diagnostic group can be seen in Fig. 2.
Cycloheximide exposure had a significant effect on
caspase activity (F =27.823, df =1, 29, p =0.000).
The average caspase activity across-groups increased
from 4 to 11 AM AFC/h/Ag protein with cyclohexi-
mide exposure. There was no statistically significantUN
CO
RR
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Fig. 2. Caspase-3 activity. The basal and cycloheximide (CHX)
induced meanFS.E.M. caspase-3 levels were determined for
fibroblast cells from patients with schizophrenia (continuous line/
circles), patients with non-schizophrenic psychosis (dotted line/
triangles) and non-affected controls (dashed line/squares).ED
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change in levels of phosphorylated P53P392Ser with
treatment (F =2.714, df=1, 29, p =0.105), although it
increased numerically from 0.7 to 0.9 optical density
units. Also, there was no statistically significant effect
of cycloheximide exposure on Bcl-2 or Bax protein
levels, or on Bcl-2:Bax ratios (see Fig. 3).
3.3. Diagnostic group effects
The MANOVA detected a significant effect of
diagnostic group on the proportion of cells in sub-G0
(F =3.487, df =2, 59, p=0.037). Tukey’s post-hoc
test revealed that this effect was due to a significant
increase ( p =0.029) in the proportion of cells in sub-
G0 in the schizophrenia group compared to the NSP
group (basal and cycloheximide exposure conditions
combined), whilst there was no difference between the
healthy comparison group and the NSP group on this
measure ( p =0.515). As can be seen in Fig. 1, this
result was mainly attributable to a significant increase
in the basal level of sub-G0 cells (t=2.117, p =0.024,
one-tailed) in the schizophrenia group (6.4%) com-
pared with the NSP group (2.8%), though this effect
was apparent at the level of a trend in the cyclohex-
imide exposed cells (5.1% versus 3.9%; t =1.443,
p=0.083, one-tailed). There was a trend for the basal
level of sub-G0 cells to be increased in the schizo-
phrenia group (6.4%) compared with the healthy
comparison group (3.8%), though again this trend did
not achieve conventional levels of statistical signifi-
cance (t=1.395, p=0.090, one-tailed). In the cyclo-
heximide exposed cells, there was no difference in the
proportion of sub-G0 cells between the schizophrenia
and healthy comparison groups (5.1% versus 5.6%;
t=0.443, p =0.33, one-tailed).
Although the MANOVA did not detect a statisti-
cally significant effect of diagnostic group on caspase
activity, there was evidence of an effect at trend level
(F =2.994, df =2, 59, p =0.06). Visual inspection of
Fig. 2 suggested that there was no difference in
caspase-3 activity levels between the three diagnostic
groups under basal conditions, but there was a
difference in the cycloheximide exposure condition.
An exploratory post-hoc t-test revealed, contrary to
hypothesis, that the schizophrenia group had signifi-
cantly less caspase-3 activity compared to the healthy
comparison group in the cycloheximide exposed
samples (t =2.246, p =0.038, two-tailed).
T
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Fig. 3. Phosphorylated P53PSer392, Bcl-2, Bax levels and Bcl-2:Bax ratio. The basal and cycloheximide (CHX) induced meanFS.E.M.
phosphorylated P53PSer392, Bcl-2, Bax levels and Bcl-2:Bax ratio were determined for fibroblast cells from patients with schizophrenia
(continuous line/circles), patients with non-schizophrenic psychosis (dotted line/triangles) and non-affected controls (dashed line/squares).
V.S. Catts et al. / Schizophrenia Research xx (2006) xxx–xxx6UN
CO
RR
EC
There was no statistically significant effect of
diagnostic group for the level of phosphorylated
P53PSer392 protein (F =0.448, df =2, 59, p =0.64),
level of Bcl-2 protein (F =0.394, df =2, 59, p =0.68),
level of Bax protein (F =2.089, df =2, 59, p=0.13), or
for the ratio of Bcl-2:Bax protein (F =1.177, df =2,
59, p =0.32). Inspection of the Fig. 3 graph headed
Bcl-2:Bax reveals that the Bcl-2:Bax ratio was
numerically lower in cells under both basal and
cycloheximide exposure conditions in the schizophre-
nia group compared with the other two groups, but
post-hoc testing did not detect significant group
differences.
3.4. Intercorrelations between apoptotic markers
Assay intercorrelations were determined to assess
whether the relationships between markers conformed
to what is known about apoptotic pathways, and to
explore group differences in these relationships. When
bivariate correlation coefficients were calculated for
apoptotic markers across diagnostic groups separately
for cells under basal and cycloheximide exposureE
conditions, there were no significant correlations
between: phosphorylated P53PSer392 and Bax levels;
Bax levels and caspase-3 activity; and caspase-3
activity and the proportion of cells in sub-G0.
Within-group intercorrelations between apoptotic
markers are presented in Table 1. There are distinct
diagnostic group differences in the overall pattern of
relationships. Under basal conditions there are signif-
icant negative correlations between Bax levels and the
Bcl-2:Bax ratio (and the absence of such a relation-
ship between Bcl-2 levels and the Bcl-2:Bax ratio) in
the healthy comparison group and the NSP group;
whereas in the schizophrenia group, there is a
significant positive correlation between Bcl-2 levels
and the Bcl-2:Bax ratio (and the absence of such a
relationship between Bax levels and the Bcl-2:Bax
ratio). In the cycloheximide exposure condition, Bax
levels are significantly negatively correlated with the
Bcl-2:Bax ratios in each of the three subject groups.
However, the expected positive correlations between
Bax levels and caspase-3, and caspase-3 and sub-G0,
are only evident in the healthy comparison group and
the NSP group. In the schizophrenia group correla-
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t1.1 Table 1
Inter-assay correlations for diagnostic groupst1.2
Basal Cycloheximide exposed cellst1.3
Bcl-2 Bax Bcl-2:Bax Caspase-3 Sub-G0 Bcl-2 Bax Bcl-2:Bax Caspase-3 Sub-G0t1.4
Healthy controlst1.5
P53 0.15 0.32 0.09 0.24 0.43 0.20 0.20 0.24 0.08 0.27t1.6
Bcl-2 0.59 0.03 0.34 0.38 0.31 0.17 0.16 0.38t1.7
Bax 0.63* 0.06 0.58 0.76* 0.33 0.07t1.8
Bcl-2:Bax 0.52 0.40 0.40 0.25t1.9
Caspase-3 0.31 0.37t1.10
t1.11
Non-schizophrenic psychosist1.12
P53 0.41 0.13 0.59 0.36* 0.15 0.32 0.22 0.32 0.46 0.34t1.13
Bcl-2 0.35 0.41 0.79* 0.03 0.33 0.07 0.32 0.02t1.14
Bax 0.64* 0.36 0.72* 0.83** 0.49 0.68*t1.15
Bcl-2:Bax 0.25 0.59 0.44 0.40t1.16
Caspase-3 0.03 0.71*t1.17
t1.18
Schizophreniat1.19
P53 0.74* 0.53 0.49 0.10 0.18 0.26 0.22 0.01 0.24 0.36t1.20
Bcl-2 0.21 0.87** 0.01 0.07 0.31 0.86* 0.43 0.19t1.21
Bax 0.26 0.45 0.01 0.71* 0.25 0.69*t1.22
Bcl-2:Bax 0.30 0.01 0.27 0.41t1.23
Caspase-3 0.47 0.62t1.24
* p b0.05t1.25
** p b0.01.
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EC4. DiscussionThe central aim of the present study was to test in a
dermal fibroblast cell model the hypothesis that there is
an increased susceptibility to apoptosis in schizophre-
nia. Supporting this hypothesis, we found an increased
proportion of cells in the sub-G0 fraction of the cell
cycle under basal culture conditions in the schizophre-
nia group compared to the NSP group. This measure
was not significantly different in the NSP group
compared to the healthy comparison group. As it is
well established that apoptotic cell bodies accumulated
in sub-G0, we interpreted this finding as being
consistent with patients with schizophrenia showing
increased basal susceptibility to apoptosis. This inter-
pretation is supported by the finding that the Bcl-2:Bax
ratio was numerically lower in the schizophrenia group
compared to the other groups, consistent with an
increased proneness to apoptosis in the schizophrenia
patient fibroblasts (Adams and Cory, 1998).EThere were no differences in caspase-3 activity
across the three diagnostic groups under basal con-
ditions. This finding is comparable to Jarskog et al.
(2004), who did not find a significant difference in the
level of caspase-3 in a postmortem tissue study of
temporal cortex in patients with schizophrenia com-
pared with healthy controls. In the cycloheximide
exposed cell lines there was a strong trend (statistically
significant on post-hoc testing) for patients with
schizophrenia to have decreased caspase-3 activity
compared with healthy controls. Hence, our findings
concerning caspase activity are not consistent with
increased susceptibility to apoptosis in patients with
schizophrenia, unless this susceptibility is caspase-3
independent. For instance, this form of susceptibility to
apoptosis could be mediated by another caspase.
Alternatively, caspase-independent susceptibility could
be mediated by the apoptosis-inducing factor (AIF),
which is essential for programmed cell death during
cavitation of embryoid bodies (Joza et al., 2001).
Further convergent evidence of schizophrenia-
specific altered apoptotic mechanism was seen in
the pattern of within-group correlations between
apoptotic pathway markers. Under basal conditions
TARTICLE IN PRESS
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the Bcl-2:Bax ratio was primarily determined by Bcl-
2 levels in the schizophrenia group, in contrast to the
two control groups where Bax was the primary
determinant of the Bcl-2:Bax ratio. In the cyclohex-
imide exposure condition the expected positive
correlations between Bax levels and caspase-3, and
caspase-3 and sub-G0, found in the two control
groups, were both negative in the schizophrenia
group. This pattern of findings may account for the
unexpected reduction in caspase-3 activity, and the
attenuated increase in the sub-G0 cell fraction, in the
schizophrenia group cultures under cycloheximide
exposure conditions.
There were limitations with the cell model used.
Dermal fibroblasts were chosen because they can be
induced to proliferate in vitro, and antipsychotic
medication effects can be minimised or eliminated
by maintaining the culture for many cell passages.
However, they do not appear to be readily suscep-
tible to apoptotic cell death. In pilot testing,
hydrogen peroxide in doses of 50, 100, 200 AM;
UV radiation (dose 19.6 J/m2); ethanol at concen-
trations of 1%, 2%, 3%, 4%, and 5%; and 100 Ag
cycloheximide/ml of media, were ineffective in
inducing cell death in the adult human dermal
fibroblasts, although it has been reported that high
concentrations (1000 AM) of H2O2 do induce
apoptosis in these cells (Uberti et al., 2002). We
chose to use a relatively high dose of cycloheximide
(200 Ag/ml) which successfully induced apoptosis
but which also impacts many biologically significant
processes in addition to those directly involved in
apoptotic or cell cycle mechanisms. Another issue
with dermal fibroblasts is that they appear to be
sensitive to small differences in experimental proce-
dures since we found that correlations between
duplicate estimates of laboratory measures were
relatively low.
The authors acknowledge that there are reasons to
view the results as preliminary and in need of
confirmation. Nonetheless, our results are in accord
with those of Jarskog et al. (2000, 2004). We found,
as this other research group found, significant
evidence of anomalous apoptotic mechanisms that
is relatively specific for schizophrenia. Investigations
of apoptosis tend to include a limited number of
molecules and use a single type of assay, for example
gene expression or protein measures. This approachED
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restricts interpretation, especially in relation to
determining whether a change is primary or second-
ary. Benes (2006) recently reported down-regulation
of pro-apoptotic markers in a postmortem gene
expression study of hippocampal tissue in schizo-
phrenia. However, as noted by Weinberger and
McClure (2002), it is impossible to determine from
gene expression studies alone whether reduced
mRNA levels of pro-apoptotic markers represents
secondary molecular compensation to cell loss from
apoptosis or primary reduction in apoptotic signaling.
However, comprehensive assessment of apoptotic
mechanisms will generate a large number of depen-
dent variables, especially if proneurotrophins and
neurotrophins are included (Lu et al., 2005; Weickert
et al., 2005). This suggests that functional studies
informed by genotyping data in large subject samples
(see Harris et al., 2005 for exemplar) may accelerate
the understanding of the significance of altered
apoptosis in schizophrenia.
In conclusion, the results of the current study
provide further evidence of disease specific aberrant
regulation of apoptosis in schizophrenia, which may
be observed in somatic cell lines, not just in brain
tissue. Although our study did not conclusively
support or refute the hypothesis, the proposal of
increased susceptibility to apoptosis in schizophrenia
continues to have heuristic value. As well as
accounting for the putative cancer resistance in
schizophrenia, it could also explain the negative
disease association between schizophrenia and rheu-
matoid arthritis (Oken and Schulzer, 1999). The
hypothesis has generated interesting genetic candi-
dates (e.g. adenomatous polyposis coli [APC] and
P53, Cui et al., 2005; Ni et al., 2005). Although
apoptotic mechanisms operate mainly to cause cell
death, there is evidence that they may occur in
neurons as a sub-lethal cellular process, called
synaptic apoptosis (Mattson and Duan, 1999; Mattson
et al., 1998) or, simply as a modulator of neuro-
plasticity (see Lu et al., 2005, in reference to
proneurotrophins). In schizophrenia, abnormalities in
synaptic apoptosis are ideal candidates to account in
part for putative anomalies in dendritic pruning
(Glantz et al., 2006) and the reported loss of prefrontal
neuropil (Selemon et al., 1995). We believe further
that large scale studies of apoptotic mechanisms in
schizophrenia are justified.
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